Cambridge Innovation Capital: Powering the Future of Deeptech and Life Sciences
Cambridge Innovation Capital (CIC) is a Cambridge-based venture capital firm backing breakthrough science and technology from one of the world’s leading innovation ecosystems. Since its founding in 2013, CIC has formed a close strategic relationship with the University of CambridgeDealroom has a profile for this one. Try Dealroom →, giving it direct access to cutting-edge research and spinouts across life sciences and deeptech.
Managing over £600 million in assets, CIC has built a portfolio of more than 40 companies, including high-profile names like Bicycle Therapeutics , Carrick Therapeutics , and Cambridge GaN Devices . With a long-term investment model, CIC not only provides capital but also operational support to help scale scientific innovation into commercially viable, global businesses.
Beyond direct investments, CIC plays a key role in supporting Cambridge’s startup pipeline through collaborations with accelerators and innovation programs. These include:
- Deeptech LabsDealroom has a profile for this one. Try Dealroom → , an accelerator supporting early-stage deeptech startups from seed to Series A;
- Start CodonDealroom has a profile for this one. Try Dealroom → , a life sciences venture builder now wholly owned by CIC, designed to accelerate the development of transformative health technologies.
Rooted in Cambridge’s vibrant research community and global in ambition, CIC is bridging the gap between academia and the market, helping to turn promising science into impactful companies.
Sources:
Cambridge Innovation Capital Website
A.M.
